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A drug (single chemical entity)
is known by several names. First,
the chemical name describes its
structure by standard chemical
nomenclature. Second, the research
code number is assigned to the
drug during pharmacodynamic
studies in animals, and often during early clinical investigation.
Third, it receives a generic name
which is often a contraction of the
chemical name, but which describes the drug and the class of
drugs to which it belongs, e.g.,
barbital, phenobarbital, pentobarbital, etc. The U.S. Adopted Name
Council (USAN), composed of representatives from the American
Medical Association, U.S. Pharmacopeia (USP), National Formulary
(NF), and Food and Drug Administration (FDA) recommends
generic names for all new drugs.
Since 1962, the FDA must approve
all generic names. Before, 1962,
the generic names were often not
descriptive of the drug, and were
confusing and difficult to use (Wilson, 1960). Fourth, the drug receives a trademarked name (brand
name), designated by a superscript ® at the end of the name,
signifying that this name has been
registered with the U.S. Patent Office. Only the registrant may use
the trademarked name for the particular drug; thus his product is
distinguished from those of competitors.
Many older drugs that are public
domain, or on which the patent
has expired, are often best known
by the generic name, e.g., phenobarbital. If a prescriber wishes to
prescribe the phenobarbital produced by Winthrop Laboratories,
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he uses the trade name Luminal.
Tetracycline HCl is the generic
name for a specific antibiotic,
which may be purchased or prescribed by that name. It is also
known by certain trade names, e.g.,
Tetracyn (J. B. Roerig & Co.) ,
Achromycin (Lederle Laboratories), Kesso-Tetra (McKesson Laboratories). Even if a company
holds an unexpired patent on a
drug, it may be the only manufacturer of. that product, so the
use of the generic name or the
trademarked name becomes immaterial, e.g., Darvon (propoxyphene
HCl, Eli Lilly & Co.) and there
can be no controversy over equivalency. On the other hand, if many
companies manufacture the same
drug, in similar dosage form, the
question arises as to whether all
these products are equivalent with
respect to physiological and pharmacological potency.

Equivalency of Generic Products
This is important because in
many instances the prescriber has
a choice of designating a product
by its generic name or by a trademarked name. If the generic name
is used, the pharmacist is permitted to dispense that drug manufactured by any company. In this
method of prescribing the assumption is that all products of a specific
generic name are equivalent. With
our present knowledge, however,
there is doubt whether products
bearing the same generic name are
equally efficacious, e.g., sulfisoxazole (F-D-C Reports, Jan. 2,
1967) . It may be that the patient
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will get less than the desired dose,
because the product does not meet
labeled claim, or that the drug cannot be absorbed for some reason,
e.g., the tablet fails to disintegrate
or dissolve. If generic products are
not equivalent, then prescribing,
either voluntary or by directive,
becomes a question of good professional practice. Forcing a prescriber to prescribe any drug in
which he does not have confidence
or with which he has no experience, is a potentially dangerous
practice.
The problem of drug designation
is further complicated in that any
manufacturer can obtain a trademark for his products, and since
all drugs now have generic names,
both terms lose their power to differentiate between the quality of
drugs. There is a new term coming
into use, "branded-generics," which
nicely bridges the gap between
generic and trademarked drugs.
Trademarks are now being obtained for both old and new generic drugs. Comparing statistics between these two groups of drugs
becomes a meaningless game of
numbers.
In addition, the trademark is
on the drug, and not on the final
product (dosage form). Yet, the
patient is not given micro-packets
of powder or liquid to take; he receives a combination of ingredients, including the drug(s), which
makes an acceptable physical entity
that can be conveniently handled,
taken, or administered.

Discrepancies in Drug Costs

The cost of medication is interwoven into this controversy. The
products sold under generic names
are often less expensive than the
trademarked products, e.g., 5 mg
dextroamphetamine sulfate tablets
may be purchased for as little as
$1.25 for a bottle of 1,000 tablets,
or purchased as Dexedrine (Smith,
Kline & French Laboratories) for
$22.60 (Drug Topics Red Book
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1967). This phenomenon of price
differentials occurs in other fields
also.
The cost of medication is confounded by the pricing structure
of many pharmaceutical manufacturers. They sell their trademarked
products to government agencies
and hospitals at much lower prices
than to the community pharmacist.
It was reported that Upjohn Co.
sold prednisone tablets (5 mg) to
the Government at $4.94 per 1000
(F-D-C Rept., July 29, 1967),
whereas the price to community
pharmacists was $20.94 (Drug
Topics Red Book 1967). It was also
reported that Ciba would give a
bottle of 1,000 tablets free with the
purchase of two bottles of 1,000
tablets of Esidrex (hydrochlorothiazide) and Esidrex K (hydrochlorothiazide and potassium chloride). This offer was made to public
and private hospitals, dispensing
physicians, but not to pharmacists
(Weekly Pharmacy Rept., Jan. 2,
1967). Price cannot be equated to
quality. If it is, one may ask if the
manufacturers are making products
of two different qualities, an expensive one of higher quality and
a less expensive one of lower quality. Recently, E. R. Squibb & Sons
announced the new price for its
Sumycin (tetracycline). The product now will sell for $4.25 per
100 capsules (F-D-C Rept., August
14, 1967). This makes Squibb's
prices more competitive with generic products.
Many of the arguments given
against the concept of generic
equivalency arose before the 1962
Kefauver hearings. These hearings
resulted in the Drug Amendments
of 1962 to the Federal Food, Drug
and Cosmetic Act. These amendments gave new regulatory powers
to the FDA , and as a result many of
the problems associated with generic drugs due to poor manufacturing practices are being reduced or
eliminated. For example, the number of drug recalls have been inceasing every year (F-D-C Rept.,
Dec. 5, 1966) , indicating that the

poorer quality products are being
forced off the market.
There are those who would like
to see products prescribed by generic name only, and those who oppose this concept. The former
group assumes generic and product
equivalency; the latter group does
not agree that products are equivalent. Unfortunately, proponents of
both sides of the question of generic equivalency have indulged in
the luxury of stating half truths.
Let us take a close look at the
major arguments presented by the
opposing sides in the generic equivalency controversy.
For Generic Equivalency

1. All generic products are
equivalent, because they must meet
USP or NF standards. If they are
equivalent, then one can buy the
least expensive product.
Reply: These compendia set
standards for purity and identification of drugs and pharmaceutical
adjuvants and for the range of
drug content in various dosage
forms. The compendia do not guarantee therapeutic efficacy or give
formulas and directions for manufacture of dosage forms sold. Some
of the tests have limited value, e.g.,
the tablet disintegration test may
not be a reliable index of drug
availability from the tablet. In
some cases, the assay may be misleading, e.g., assay for total iodine
in Thyroid USP (Brune et al., 1962;
Gatz, Ginsburg, and Salenger,
1962; MacGregor, 1961; Williams,
Meister, and Florsheim, 1963).
Yet the standards prescribed by
these compendia generally reflect
present day manufacturing practices, because the committees which
establish the standards include industrial scientists.
2. The Defense Personnel Support Center buys only generic products. If these products are used
in the Bethesda hospitals and given
to our Presidents, generals, and
Congressmen, etc., why are they
not good enough for everybody?
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Reply: The Defense Department
buys its drugs under generic names
based on competitive bidding. Since
all drugs have generic names, and
anyone can make generic drug
products not covered by unexpired
patents, the bidding is open to all.
The Defense Department inspects
the manufacturing facilities before
accepting any bid. After the product is made, representatives from
the department again come to the
manufacturer to observe all the
final tests performed on the product. By this procedure the Defense
Department presumably receives a
product that meets all its specifications. Not even a large hospital,
let alone individual pharmacists,
can make these inspections. The
manufacturer of trademarked products competes under this system and
when successful, sells his trademarked product under its generic
name.
As the FDA increases the number
of inspectors and is able to enforce
its regulations more widely, drug
products should be of higher quality, because more manufacturers
will be operating under good manufacturing practices and with sufficient quality control.

Against Generic Equivalency
1. The large manufacturers of
trademarked products are engaged
in research to improve existing
drugs and to discover new drugs.
The prices of their drug products
must be higher to support this research. The small manufacturers
of generic products do not engage
in research, and have never discovered a new drug.
Reply: The companies who undertake research, do not do it for
altruistic reasons. They do it to
gain competitive advantages and to
make money. This is not to be condemned, but do not ask for public
support for it. Many other industries do research and support research, e.g., chemical, electrical,
petroleum, etc., but they ,do not

ask for public sympathy. The pharmaceutical industry's research efforts do not justify the large price
differentials that often exist many
years after the product has been
introduced, even if the successful
products must pay for the failures.
Companies that discover a new,
unique, and useful medicinal can
obtain a patent which runs for 17
years after the date of issue (about
three years after application). During this time they have a monopoly
on this drug, and there is no competition, generic or otherwise. In
this manner they can protect their
investment and make a profit.
2. The large manufacturers of
trademarked products have better
quality control and can spend more
time and money in the pursuit of
excellence. Their products are
purer and there is less likelihood
of contamination.
Reply: This should be true, but
they are not immune to mistakes
and accidental contamination. This
difference is slowly being reduced
by increasing FDA inspections, and
hopefully, this difference will continue to diminish. Mr. Hansen,
program operations director of the
Bureau of Regulatory Compliance
FDA, stated that there were less
than 70 recalls per year before
1962; there were 110 in 1964, 340
in 1965, and 449 in 1966. Of the
449 violations in 1966, 351 (78%)
were due to violations of the good
manufacturing practice regulations
(F-D-C Rept., Dec. 5, 1966).
Purity and control of contamination is a problem that has plagued
all manufacturers. Contamination
due to diethylstilbesterol (Weber
et al., 1963), estrogen (Hertz,
1958), selenium (Keller, 1960),
penicillin, Salmonella, metal particles in opthalmic ointments, etc.,
have occured in products of both
large and small manufacturers.
They are more likely to occur due
to poor manufacturing practices. In
1953, a study of vitamin preparations in Canada showed that subpotent products were produced
more often under conditions of

inadequate quality control than
those manufactured under adequate control (Campbell, 1953).
3. The trademark is the identification of the manufacturer, and
says he assumes responsibility for
the product.
Reply: True! Many manufacturers are concerned about their
"good name," and, therefore, may
exercise better quality control. All
manufacturers are responsible for
their products whether they have
a trademark or not. A trademark,
however, is not synonymous with
quality; anyone can obtain trademarks for his products.
4. Physicians, dentists, etc., prescribe by trademark because they
are familiar with the company and
its products and know the therapeutic results to expect from these
products.
Reply: True! But, do they really
know the company? How much of
the prescriber's information comes
from the company representative,
and how complete is that information? Ciba was accused of not
reporting toxicity data on Elipten
(amine-glutethimide) (FDA Rept.,
1966). Frosst made an inadvertent
mistake in its reformulation of
Dicumerol (bishydroxycoumarin)
(Lozinski, 1960) . Cannot the
physician just as well become acquainted with certain companies
that manufacture nonproprietary
pharmaceuticals?
5. Some formula ingredients in
a dosage form make generic prescribing hazardous for patients with
certain diseases that require restricted caloric or sodium intake.
When the physician prescribes by
trademark, he knows what the patient will be getting.
Reply: How does the physician
know what .the ingredients other
than the drug are? This information is not always readily available
to the prescriber. The manufacturers do not list tablet formula ingredients and their amounts. One
gram of sugar produces about four
calories and no tablet would contain this much sugar as a diluent.
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The prescriber must write to the
company to ascertain the ingredients.
It is possible that a large manufacturer may be more concerned
as to the ultimate user of his product, and therefore make adjustments in his formulation, e.g., omit
calorie producing materials or
sources of sodium ion. He would
state this in the package inserts,
etc.
6. When a generic product is
prescribed, the same product is
not always dispensed. This can lead
to varying therapeutic results. A
trademark or designation of the
manufacturer insures that the same
product is always dispensed.
Reply: The same product should
always be dispensed unless it is no
longer available. The source of the
generic product should be noted
on the prescription order by the
pharmacist, to insure that the same
product is dispensed when the prescription order is refilled.
When a patient is on long term
drug therapy, e.g., insulin, penicillin, anticoagulants, thyroid, etc., a
constant drug blood level in the
therapeutic range is necessary to
prevent relapse. A reliable product
which will give the same absorption pattern is necessary. Changing
brands may result in different levels
of the drug in the blood. The second brand may be satisfactory for
a patient just starting on the therapy regimen, but may not be satisfactory for refilling of a prescription order. Dosage adjustment is
easiest when the patient is just
starting therapy. The prescriber
learns what to expect from each
product regardless of the name.
7. The pharmacist has greater
liability when filling prescriptions
for products prescribed generically.
Reply: True, but what does this
have to do with the proper treatment of patients?
If a trademarked product is prescribed, or the manufacturer of the
product is stated on the prescription order, then the pharmacist has
no choice as to what to dispense,
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and he is only liable under the implied warranty doctrine. If a generic product is requested and the
manufacturer not designated, then
the pharmacist has a choice. If he
uses care and exercises his knowledge and experience to choose a
reliable product from a source in
which he has confidence, then he
cannot be considered negligent, but
the implied warranty doctrine still
applies. Since the product is sold
in interstate commerce, a new drug
application has been approved by
the FDA, so that the pharmacist
does not have to guarantee efficacy.
When products are prescribed by
generic name, the pharmacist has
more responsibility and hence
more liability, but he should be
willing to accept this.
8. Products sold under non-proprietary names do not maintain
their potency as well as proprietary
products.
Reply: This is one of the quickest tests that can be performed on
a product by the FDA or a state
agency. Judging from the results
reported in the Medical Letter
(Aug. 19, 1960), potency is rarely
outside the set limits. On the other
hand, taking the data collected by
the analyst of the city of Birmingham, England, it appears that the
potency of many English products
does not meet official requirements
(Bagnall and Stock, 1955). There
is not sufficient published data
available at this time to determine
if this statement is true.
9. The large manufacturer has
more staff, facilities, information,
and manufacturing "know how"
than the small company. Therefore
the large manufacturer is better
able to produce a more stable,
uniform, and efficacious product.
Reply: The large manufacturers
do not have a monopoly on information and the small manufacturer can hire knowledgeable and
experienced personnel. The good
manufacturing practice regulations
and their interpretation are available to all. A great deal of stability
data and incompatibility informa-

tion has been published. Unfortunately, however, the availability of
this information does not guarantee
its application. The FDA has this
knowledge too, and uses it in judging new drug applications, and in
their plant inspections.
The argument does not end here.
It has been demonstrated many
times that there are numerous factors in the formulation and manufacture of dosage forms that may
affect the efficacy of the product.
Levy and Nelson (1961) and Delgado and Cosgrove ( 1963) review
this problem in detail. These authors discuss the effect of variables
such as drug particle size, sterility
of ophthalmic preparations, rubber
and polymer closures on multidose
vials, ingredients of ointment and
suppository bases, salts and esters
of the parent drug molecules, and
the ingredients added to the drug
to permit manufacture of the dosage form such as solvent, sufactant,
and fillers.
A commonly used filler for tablets and capsules, dicalcium phosphate, was found to depress blood
concentration of tetracycline (Boger, 1959) . Drug particle size may
affect absorption of both oral and
parenteral product (Levy, 1963a),
e.g., sulfa drugs, griseofulvin, and
insulin. Increasing the solubility of
the tablet base increased the absorption of spironolactone (Levy,
1962). "Sgft" tablets of phenylindanedione produced drug blood
levels similar to that produced by
loose powder in capsules, whereas
"hard" tablets gave delayed and
poor absorption (Schulert and
Weiner, 1954). The salt form of
PAS and the presence or absence
of an enteric coating influenced
the PAS blood level (Frostad ,
1961). The salt form, molecular
modification, and the formulation
of aspirin tablets affected the salicylate blood level (Leonards, 1963 ;
Levy and Gagliardi, 1963; Levy
and Sahli, 1962). An in vitro test
to determine the dissolution rate
of a drug has explained why certain drug products, such as predni-
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sone (Campagna et al., 1963) and
tolbutamide (Levy, 1963b), were
reportedly poorly absorbed. In an
investigation of 18 commerically
available tolbutamide tablets, it
was found that the amount of drug
dissolved at the end of one hour
varied from 30% to 86% (Brudney, Stewart, and Eustace, 1963).
In vitro studies (Levy et al., 1963;
Levy and Gumtow, 1963) have
shown several factors that influence the rate of tablet dissolution.
Studies have shown that in commerically available sustained release products, drug absorption
may vary from complete absorption immediately (no sustained effect) to almost no absorption
(Shenoy, Chapman, and Campbell,
1959).
Stability of a product is important not only because the potency
of the product must be maintained,
but also because the decomposition
products may produce untoward
reactions, e.g., tetracycline (Frimpter et al., 1963; Editorial, J. Am.
Med. Assoc. , 1963).
Isolated clinical cases have been
reported in which a generic product gave poorer results than a
trademarked product, e.g., prednisone (Keller, 1960), cortisone
(Rosenheim and Ross, 1958, Boch,
19 59; Bayliss, 19 59), tolbutamide
(Carter, 1963; Caminetsky, 1963),
and phenylbutazone (Searl and
Pernarowski, 1967) . Even if ineffectiveness has not been shown,
it may still be there.
We have learned much about the
formulation and manufacture of
dosage forms, often only after the
product has been marketed. Oversights, even by large manufacturers, have come to light in this manner. The large manufacturer has
the personnel and the facilities that
would seem to make him more
able to do thorough investigations
before marketing a product, but
he has not always done so.
The large companies also have
produced drugs for a very limited
market as a public service, because
the drug is needed. This is not an

argument against generic equivalency.
Conclusion
The truth about generic equivalency has not yet been determined.
The arguments in the generic equivalency controversy are confounded
by names, proprietary (trademark,
brand name) as opposed to nonproprietary (generic, branded-generic), yet quality of the products
is not necessarily related to any
name. The efficacy and not the
name of the product is important.
The crucial question to ask is
whether the product is clinically
or therapeutically effective, giving
reliable and uniform results.
Drugs called by their generic
names are here to stay and more
than likely their use will increase,
especially as state and federal
governments pay more of the medication bills. Kentucky and Louisiana already have issued lists of
generic equivalents to trademarked
products.
Meanwhile, the prescriber and
the pharmacist still must ponder
the question of therapeutic equivaIency of drug products. What product is to be requested on a prescription order and what product
is to be dispensed if the drug is
prescribed by its generic name.
More information is needed to answer this question. Clinical trials
testing the hypothesis of generic
equivalency are required. A national clearing house for information on the efficacy of drug products may be necessary. A national
organization such as the American
Pharmaceutical Association, American Medical Association, or the
FDA, or an organization composed
of representatives of interested
groups could collect and disseminate the information to physicians,
dentists, pharmacists, etc.
The U.S. Pharmacopeia and National Formulary monographs
should include formulas and manufacturing directions for the various
drug products. The specifications
should be based on clinicaI!y dem-

onstrated efficacy. The monographs
could also include information on
known factors that may impair
the effectiveness of the product.
Formula and process variations
would be permitted only if the
same therapeutic results can be
demonstrated clinically.
The knowledge that the Defense
Department has concerning its
drug purchases and the use of these
products in its facilities could be
made available. Manufacturers,
both large and small, could make
available clinical and physiochemical data on their products, such
as assay, drug content variation per
unit dose, tablet dissolution rates,
drug levels in blood or urine, and
stability. It is important that the
FDA or the proper state agency be
informed of any suspected drug
products so that substandard products may be removed from the
market as rapidly as possible.
Finally, it is necessary that more
people become aware of the true
magnitude of the problem of generic equivalency. Because of the
present Jack of knowledge of which
drug products are therapeutically
equivalent, the prescriber and pharmacist must rely on their experience as to which products and
companies are reliable. They must
also continually search their journals for information on the therapeutic equivalency of products.
Perhaps the pharmacist should compile information on generic and
therapeutically equivalent drug
products, which companies consistently make poor products, using
sources as Weekly Pharmacy Reports (The Green Sheet), F-D-C
Reports (The Pink Sheet), FDA
Papers (U.S. Government Printing
Office), and The Medical Letter on
Drugs and Therapeutics. These
compilations would then be available for the prescriber.
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